Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene ... The ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...

In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

US biopharma Kymera Therapeutics, which is developing a new class of small molecule medicines using targeted protein degradation (TPD), has announced an important update on its pipeline.

More companies outside Houston are looking at new drug development models built here, one life sciences CEO says.

Cash Balance: $911 million, providing a cash runway to mid-2027. Kymera Therapeutics Inc (NASDAQ:KYMR) has advanced KT-621 into the clinic, marking a significant milestone with a promising drug ...

Cash Balance: $911 million, providing a cash runway to mid-2027. Kymera Therapeutics Inc (NASDAQ:KYMR) has advanced KT-621 into the clinic, marking a significant milestone with a promising drug ...

On Thursday, Jefferies, a global investment banking firm, updated its outlook on Kymera Therapeutics (NASDAQ:KYMR), raising the price target to $59.00 from the previous $44.00. The firm has ...

On Thursday, Jefferies, a global investment banking firm, updated its outlook on Kymera Therapeutics (NASDAQ:KYMR), raising the price target to $59.00 from the previous $44.00. The firm has maintained ...